Polymerase News and Research

RSS

Rice, UTMB develop diagnostic test for cryptosporidiosis

Bioengineers at Rice University and the University of Texas Medical Branch (UTMB) at Galveston have developed a simple, highly sensitive and efficient test for the diarrheal disease cryptosporidiosis that could have great impact on global health.

7 Feb 2014

Splicing findings offer lung cancer clues

Researchers from Spain have identified several new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer, suggesting that their dysregulation is involved in the pathogenesis of the disease.

4 Feb 2014

Researchers identify components of C. diff bacteria that can be used to develop better treatment

Rhode Island Hospital researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in the U.S. The study is published online in advance of print in the Journal of Molecular Diagnostics.

31 Jan 2014

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

Porvair Sciences has announced a new Chromatrap Enzymatic Shearing Kit that contains all the necessary reagents and buffers for up to 10 chromatin preparations.

From Chromatrap® - Porvair Sciences Ltd 27 Jan 2014

Researchers identify molecular mechanism by which cocaine alters brain's reward circuits, causes addiction

Researchers from the Icahn School of Medicine at Mount Sinai have identified a new molecular mechanism by which cocaine alters the brain's reward circuits and causes addiction.

21 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

Vaccines for whooping cough contain 3 to 5 protective antigens

Vaccines for whooping cough contain three to five protective antigens, the presence of which are critical to the vaccine's effectiveness. But one of the antigens, pertactin, which had been present in almost all isolates of Bordetella pertussis in the US as late as 2010, is now absent from more than half of them, according to a paper published ahead of print in Clinical and Vaccine Immunology.

13 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

New method uses lab-on-a-chip device and cell phone to determine concentration of molecules

In developing nations, rural areas, and even one's own home, limited access to expensive equipment and trained medical professionals can impede the diagnosis and treatment of disease.

21 Nov 2013

Researchers discover new human enzyme that facilitates DNA repair during DNA copying process

Every day, the human body produces new cells to regenerate tissues and repair those that have suffered injury. Each time this happens, the cells make copies of their DNA that they will pass on to the resulting daughter cells. This process of copying the DNA, also called replication, is very delicate, given that it can generate severe alterations in the DNA that are associated with malignant transformation or ageing.

21 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

Gladstone-led study sheds light on critical molecular process

One of biology's most fundamental processes is something called transcription. It is just one step of many required to build proteins-and without it life would not exist. However, many aspects of transcription remain shrouded in mystery. But now, scientists at the Gladstone Institutes are shedding light on key aspects of transcription, and in so doing are coming even closer to understanding the importance of this process in the growth and development of cells-as well as what happens when this process goes awry.

8 Nov 2013

Researcher receives grant to explore HER2-positive breast tumor susceptibility to PARP inhibitors

Shih-Hsin (Eddy) Yang, M.D., Ph.D., the ROAR Southeast Cancer Foundation Endowed Chair in the University of Alabama at Birmingham Department of Radiation Oncology, has received a $450,000 grant from Susan G. Komen for the Cure to further investigate HER2-positive breast tumor susceptibility to PARP inhibitors.

10 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...